Clinical Trial Update: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating hydroxychloroquine in combination with encorafenib and either cetuximab or panitumumab for metastatic colorectal cancer w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer with Braf V600e Mutation

Drugs mentioned

• Cetuximab (cetuximab)
• Encorafenib (encorafenib)
• Hydroxychloroquine (hydroxychloroquine)
• Panitumumab (panitumumab)

Snippet

Sponsor: Northwestern University | Conditions: Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer | Phase 2 | Status: RECRUITING